Hallucinations

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave

Retrieved on: 
Tuesday, June 22, 2021
Branches of biology, Hallucinations, Biology, Medicine, Biomarkers, Psychedelia, Psychedelic drug, Hallucinogen, Psychedelic experience, Genetic testing

To drive brand awareness of, and access to, HaluGen's Psychedelics Genetic Test Kit

Key Points: 
  • The genetic test, a first of its kind, identifies specific DNA biomarkers to gauge the risk and potential of adverse reactions toward hallucinogenic drugs.
  • The test also provides insights into the short- and long-term potential of psychedelic-induced risks, such as psychosis.
  • This is just one of many steps we plan to take as we work to develop channels for the commercial development of HaluGen's Psychedelics Genetic Test," said Entheon Biomedical Chief Executive Officer, Timothy Ko.
  • "Our mutual vision to help create safer psychedelic experiences and help people make informed choices remains paramount to the core mission of Entheon."

June Psychedelic Capital Marks Annual Birthday of Conference Series

Retrieved on: 
Monday, June 21, 2021
Hallucinations, Newsfile, Psychedelic drug, Psychoactive fungi, Entheogens

Toronto, Ontario--(Newsfile Corp. - June 21, 2021) - Microdose Psychedelic Insights is proud to announce the upcoming Psychedelic Capital: June 2021 conference to be taking place on June 30, 2021.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - June 21, 2021) - Microdose Psychedelic Insights is proud to announce the upcoming Psychedelic Capital: June 2021 conference to be taking place on June 30, 2021.
  • Part of an investor conference series diving deep into psychedelic medicine investment, Psychedelic Capital conferences seek to introduce investors and attendees with a curated group of CEOs, capital advisors, and investment luminaries from around the world.
  • The conference will subsequently play host to a number of corporate presentations, including:
    Gwella Mushrooms, a Toronto-based company dedicated to the research, production and distribution of medicinal mushroom-based products.
  • Additional information about the Psychedelic Capital: June 2021 conference, as well as details for registration, can be found here: https://microdose.buzz/pressrelease

New Study Asks Clinicians to Help Shape the Future Of Psychedelic Integration Therapy

Retrieved on: 
Monday, June 21, 2021
Hallucinations, Psychedelic drug, Clinical medicine, Medical specialties, Medicine, Psychotherapy, Relationship counseling, Rehabilitation medicine, Occupational therapy, Play therapy

With the support of Osmind, participating clinicians will be able to quickly and easily contribute research that will help shape the future of psychedelic integration therapy.

Key Points: 
  • With the support of Osmind, participating clinicians will be able to quickly and easily contribute research that will help shape the future of psychedelic integration therapy.
  • Integration therapy involves work with clients before, during, and/or after a psychedelic experience.
  • Researchers say the study will give them a better sense of why patients turn to psychedelic integration therapy and how practitioners can best serve their varying needs.
  • The study will also seek to gain a better understanding of how psychedelic use in non-medical settings is driving the current demand for integration therapy.

Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences and Silo Wellness Announces Psychedelics Genetic Test Kit Partnership

Retrieved on: 
Thursday, June 17, 2021
Hallucinations, Medicine, Branches of biology, Clinical medicine, Medical genetics, Psychedelic drug, Hallucinogen, Genetic testing

The intention of the Agreement is for Silo Wellness to provide referral and marketing services for HaluGen's Psychedelics Genetic Test, representing an opportunity to expand access and visibility for the test, which was launched in the US on June 6, 2021.

Key Points: 
  • The intention of the Agreement is for Silo Wellness to provide referral and marketing services for HaluGen's Psychedelics Genetic Test, representing an opportunity to expand access and visibility for the test, which was launched in the US on June 6, 2021.
  • Silo Wellness will receive compensation on each referral made to HaluGen.
  • The genetic test, a first of its kind, identifies specific DNA biomarkers in order to gauge the risk and potential of adverse reactions toward hallucinogenic drugs.
  • "Increased visibility and access to the Psychedelics Genetic Test through Silo Wellness' broad network furthers our commitment and ability to provide tools and knowledge to help individuals make informed decisions surrounding the consumption of psychedelics."

Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

Retrieved on: 
Thursday, June 17, 2021
Hallucinations, Amines, Entheogens, Psychoactive drugs, Ayahuasca, N,N-Dimethyltryptamine, Hallucinogen, Pharmacokinetics, Psychedelic drug, Life sciences

The planned Phase 1 study will investigate the safety, tolerability and pharmacokinetics of intravenous DMT infusion in healthy volunteers with no prior history of psychedelic exposure.

Key Points: 
  • The planned Phase 1 study will investigate the safety, tolerability and pharmacokinetics of intravenous DMT infusion in healthy volunteers with no prior history of psychedelic exposure.
  • Specifically, the trial will aim to identify a sub-hallucinogenic dosing regimen to support planned clinical studies in stroke patients.
  • While there are many companies that are working in or attempting to enter the psychedelic drug space, many are a considerable distance from human studies, said Christopher J. Moreau, CEO of Algernon pharmaceuticals.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

/R E P E A T -- Braxia Scientific to Present at the Psychedelics in Psychiatry and Beyond Virtual Conference Hosted by H.C. Wainwright & Co. on June 17, 2021/

Retrieved on: 
Wednesday, June 16, 2021
Psychoactive drugs, Drugs, Psychiatric diagnosis, Hallucinations, Entheogens, Psilocybin, Ketamine, Major depressive disorder, Psychedelic drug

Braxia's CEO, Dr. Roger McIntyre will present and participate in a panel discussion, "Patient Experience And Commercial Considerations When Launching Psychoactive Agents In Psychiatry."

Key Points: 
  • Braxia's CEO, Dr. Roger McIntyre will present and participate in a panel discussion, "Patient Experience And Commercial Considerations When Launching Psychoactive Agents In Psychiatry."
  • The medical solutions company aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.
  • The Company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.
  • The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

“The Science Behind Using Psychedelics To Treat Mental Health Disorders And Addiction Is Compelling”

Retrieved on: 
Wednesday, June 16, 2021
Psychiatry, Mind, Psychology, Hallucinations, Psychedelic drug, Mental health, Mental disorder

ATLANTA, June 16, 2021 (GLOBE NEWSWIRE) -- Jim Cramer discussed psychedelics on his June 15, 2021 program and said, The science behind using psychedelics to treat mental health disorders and addiction is compelling."

Key Points: 
  • ATLANTA, June 16, 2021 (GLOBE NEWSWIRE) -- Jim Cramer discussed psychedelics on his June 15, 2021 program and said, The science behind using psychedelics to treat mental health disorders and addiction is compelling."
  • The real money in psychedelics will be made from FDA approved drugs for the treatment of depression and mental health.
  • As a result, mental health disorders are on the rise in every country and could cost the global economy up to $16 trillion annually by 2030.
  • MindMeds business is premised on a growing body of research supporting the use of psychedelics to treat a myriad of mental health problems.

Braxia Scientific to Present at the Psychedelics in Psychiatry and Beyond Virtual Conference Hosted by H.C. Wainwright & Co. on June 17, 2021

Retrieved on: 
Wednesday, June 16, 2021
Psychoactive drugs, Drugs, Psychiatric diagnosis, Hallucinations, Entheogens, Psilocybin, Ketamine, Major depressive disorder, Psychedelic drug

Braxia's CEO, Dr. Roger McIntyre will present and participate in a panel discussion, "Patient Experience And Commercial Considerations When Launching Psychoactive Agents In Psychiatry."

Key Points: 
  • Braxia's CEO, Dr. Roger McIntyre will present and participate in a panel discussion, "Patient Experience And Commercial Considerations When Launching Psychoactive Agents In Psychiatry."
  • The medical solutions company aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.
  • The Company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.
  • The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies

Retrieved on: 
Tuesday, June 15, 2021
Entheogens, Psychoactive drugs, Hallucinations, Cacti, Mescaline, Native American Church, Psychedelic drugs, Branches of biology, Psychedelic music, Psilocybin, GNU Multiple Precision Arithmetic Library, Software

The audio press release covers XPhytos recent announcement regarding the status of its GMP mescaline synthesis program.

Key Points: 
  • The audio press release covers XPhytos recent announcement regarding the status of its GMP mescaline synthesis program.
  • To hear the audio production, visit: https://www.nnw.fm/GFUhh
    To read the original press release, visit: https://www.nnw.fm/dcaCA
    "With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto's psychedelic medicine program is progressing on schedule.
  • As the manufacturing programs advance, we look forward to focusing our expertise on psychedelic drug formulation," said Hugh Rogers, CEO & Director.
  • IBN is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions.

Dimensions Health Centres to Provide Funding for Psychedelics Research Collaborative at Queen’s University

Retrieved on: 
Tuesday, June 15, 2021
Hallucinations, Psychedelic drug

TORONTO, June 15, 2021 (GLOBE NEWSWIRE) -- Dimensions Health Centres (Dimensions), a psychedelic wellness companyoffering immersive retreats for reset and renewal,will provide funding to the Faculty of Health Sciences at Queens University, to help launch a collaborative space for research and innovation in the field of psychedelics.

Key Points: 
  • TORONTO, June 15, 2021 (GLOBE NEWSWIRE) -- Dimensions Health Centres (Dimensions), a psychedelic wellness companyoffering immersive retreats for reset and renewal,will provide funding to the Faculty of Health Sciences at Queens University, to help launch a collaborative space for research and innovation in the field of psychedelics.
  • The Dimensions Health Fund in support of the Study of Psychedelics will assist Queens in launching a psychedelics research collaborative, which will take a multi-pronged approach to fostering research and innovation in psychedelic-focused therapies.
  • We are confident that the research and development at Queens will shape the psychedelics industry for years to come.
  • Founded in Toronto in 2021, Dimensions is a founding partner of the Psychedelics Research Collaborative at Queens University.